Expert Consulting Services

Helping You Navigate the Changing Healthcare Landscape with Confidence

How do you plan to navigate the new CMS programs?

If you’re unsure about the changing regulatory requirements, new payment models and the complexities of the various government programs, you are not alone.

Miraca’s team of certified health IT advisors are here to help you navigate the changing healthcare landscape with confidence. When you choose Miraca, you work directly with one of our knowledgeable consultants who help guide your office every step of the way.

  • Understand CMS reporting rules
  • Get help with choosing which measures to report on
  • Learn the steps you can take now to succeed with Medicare quality reporting
Road Image

What is MACRA and how does it affect providers?

MACRA is the Medicare Access and CHIP Reauthorization Act. MACRA replaces the current Medicare reimbursement schedule with a new pay-for-performance program that’s focused on quality, value, and accountability. This new system, called the Quality Payment Program (QPP), repeals the Sustainable Growth Rate Formula and is made up of two participation tracks for payment—

  • Merit-Based Incentive Payment System (MIPS)
  • Advanced Alternative Payment Models (APMs)

If you are a clinician that bills services under the Medicare Physician Fee Schedule, understanding the requirements and payment changes under MACRA is crucial. The steps you take today will hit your practice’s bottom line tomorrow.

The first measurement period for the Quality Payment Program began January 1, 2017.



Helping Practices Avoid Penalties & Capture Incentives

Miraca’s own health IT consultants have helped thousands of eligible clinicians and centers. Our certified advisors have provided comprehensive support for more than five years.

MIPS — Are you ready for the newest requirements?

If you’ve attested for CMS Quality Programs, are you ready for an audit—or trying to move forward after one?

Let Miraca’s health IT consultants help your practice with:

  • Registration
  • Workflow training on each measure
  • Ongoing report review for each EC (eligible clinician)
  • Attestation and audit support for each EC
  • HIPAA compliance
  • Security assessments

Quality — Understand which measures to report, options for reporting, and how to seamlessly embed quality data reporting into your practice.

Cost — Get help with avoiding penalties and analyzing your new QRUR report as the industry goes to a pay-for-performance model.

Clinical Practice Improvement Activities (CPIA) — Let Miraca help your practice select activities that easily align with new requirements and the workflow of your practice and the patients you serve.


Physician Compare Optimization — Ensure that your physicians are top-rated in your community. The new CMS Physician Compare website provides information for consumers. The site encourages consumers to make informed healthcare decisions. Through this, the site also creates explicit incentives for physicians to maximize their performance.

Both Physician Compare and MACRA scores will be published annually.

ASC Reporting — ASCs need to be ready to report the annual required data for ASC-6, 7, 8, 9 and 10, as well as complete a security risk assessment.

Experience Matters!

Our expert technical consultants have a wealth of experience:

  • Assisted more than 600 practices
  • 100% success in 2015 & 2016 with clients who have been audited by CMS!
  • More than 800 security risk analyses performed
  • Authors, trainers, coaches and certified HIT specialists
  • Meet author Joy Rios, one of our distinguished consultants
  • See what our clients say!

Contact Miraca Life Sciences to learn how Miraca can assist your practice.
Call 866.588.3280 or email HealthITConsulting@MiracaLS.com

We have been using Miraca for about 20 months, and they are outstanding. They have a daily conference with all of their Dermpaths across the country where they [collaborate on] tough cases.
— Joel Cohen, MD


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News


May 23, 2017

Miraca Life Sciences Again Expands Therapeutic Drug Monitoring with Addition of First Biosimilar Inflectra®

IRVING, Texas, May 23, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, has further expanded its InformTx™ therapeutic drug monitoring (TDM) capabilities with the addition of testing for Inflectra® (infliximab-dyyb), which is the first biosimilar drug in the test offering. Since launching InformTx in June 2016, Miraca Life Sciences has expanded the service from four to […]

Continue reading


April 18, 2017

Miraca Research News: Philips receives FDA clearance to market Philips IntelliSite Pathology Solution for primary diagnostic use in the US

Pathologists at Miraca Life Sciences contributed significantly in the development of a new product from Philips, the IntelliSite Pathology Solution. As one of four clinical study sites, Miraca Life Sciences participated in “one of the largest studies ever conducted to directly compare the use of digital pathology to optical microscopes.” At Miraca, participation in the Philips study was a project of Miraca […]

Continue reading


April 11, 2017

Ten Research Projects from Miraca Life Sciences Accepted for DDW Conference

IRVING, Texas, April 12, 2017 — Ten research projects from the GI pathologists at Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Digestive Disease Week® conference (DDW), which will be held May 6–9 in Chicago. DDW is the world’s largest gathering of physicians, researchers and industry in the fields of gastroenterology, […]

Continue reading


March 27, 2017

Simponi® is Sixth Drug in InformTx™ Therapeutic Drug Monitoring Service from Miraca Life Sciences

IRVING, Texas, March 28, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand its InformTx™ therapeutic drug monitoring (TDM) capabilities, now testing for Simponi (golimumab) as well as patient-developed antibodies to Simponi. This is the first TDM assay available in the United States for Simponi. With this addition, Miraca Life Sciences now performs TDM […]

Continue reading


November 30, 2016

Stelara® Now Available for Therapeutic Drug Monitoring from Miraca Life Sciences

IRVING, Texas, December 1, 2016 — Miraca Life Sciences, the largest U.S. independent anatomic pathology lab, has expanded its InformTx™ therapeutic drug monitoring service for drugs that treat inflammatory bowel disease (IBD) with the addition of Stelara (ustekinumab).

Miraca Life Sciences continues to perform therapeutic drug monitoring (TDM) for Remicade® (infliximab), Humira® (adalimumab), Cimzia® (Certolizumab pegol) and Entyvio® (vedolizumab). Since […]

Continue reading